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Background: PTOV1 is an adaptor protein with functions in diverse processes, including gene transcription and
protein translation, whose overexpression is associated with a higher proliferation index and tumor grade in
prostate cancer (PC) and other neoplasms. Here we report its interaction with the Notch pathway and its
involvement in PC progression.
Methods: Stable PTOV1 knockdown or overexpression were performed by lentiviral transduction. Protein
interactions were analyzed by co-immunoprecipitation, pull-down and/or immunofluorescence. Endogenous gene
expression was analyzed by real time RT-PCR and/or Western blotting. Exogenous promoter activities were studied
by luciferase assays. Gene promoter interactions were analyzed by chromatin immunoprecipitation assays (ChIP). In
vivo studies were performed in the Drosophila melanogaster wing, the SCID-Beige mouse model, and human
prostate cancer tissues and metastasis. The Excel package was used for statistical analysis.
Results: Knockdown of PTOV1 in prostate epithelial cells and HaCaT skin keratinocytes caused the upregulation,
and overexpression of PTOV1 the downregulation, of the Notch target genes HEY1 and HES1, suggesting that
PTOV1 counteracts Notch signaling. Under conditions of inactive Notch signaling, endogenous PTOV1 associated
with the HEY1 and HES1 promoters, together with components of the Notch repressor complex. Conversely,
expression of active Notch1 provoked the dismissal of PTOV1 from these promoters. The antagonist role of PTOV1
on Notch activity was corroborated in the Drosophila melanogaster wing, where human PTOV1 exacerbated Notch
deletion mutant phenotypes and suppressed the effects of constitutively active Notch. PTOV1 was required for
optimal in vitro invasiveness and anchorage-independent growth of PC-3 cells, activities counteracted by Notch,
and for their efficient growth and metastatic spread in vivo. In prostate tumors, the overexpression of PTOV1 was
associated with decreased expression of HEY1 and HES1, and this correlation was significant in metastatic lesions.
Conclusions: High levels of the adaptor protein PTOV1 counteract the transcriptional activity of Notch. Our
evidences link the pro-oncogenic and pro-metastatic effects of PTOV1 in prostate cancer to its inhibitory activity on
Notch signaling and are supportive of a tumor suppressor role of Notch in prostate cancer progression.
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The PTOV1 gene and protein are expressed at increased
levels in PC [1-4] and other tumors [5,6]. PTOV1 ex-
pression is detected in putative pre-neoplastic lesions
of atypical adenomatous hyperplasia (AAH) [7] and its
detection in pre-neoplastic high-grade prostate intrae-
pithelial neoplasia (HGPIN) lesions from prostatic bi-
opsies may be helpful in the early diagnosis of PC [8].
The protein consists of a tandem repeated domain, also
present as a single copy in PTOV2, or MED25, a subunit
of the Mediator transcriptional complex [1,9,10], conserved
among higher eukaryotes, that uses novel structural modes
to recruit the VP16 activation domain [11-13]. Recently,
PTOV1 was shown to repress the MED25-mediated
transcription of the retinoic acid (RA) receptor [14],
suggesting a potential molecular mechanism underlying
resistance to RA [15]. Additionally, PTOV1 may interact
with the lipid-raft associated protein Flotillin-1 [16], the
phosphoserine-recognizing protein 14-3-3σ [17], the BUZ/
Znf-Ubp domains of the Histone deacetylase HDAC6 [18],
and the ribosomal protein RACK1 [19]. Although it is diffi-
cult to ascertain how each of these interactions contributes
to a possible role of dysregulated PTOV1 expression in
cancer progression, this protein modulates cell prolifera-
tion, cell cycle progression [4,16], protein synthesis and
gene transcription [15,19,20]. Combined these observations
suggest a function for PTOV1 as an adaptor protein impli-
cated in different cellular events and locations.
Here we report a functional interaction of PTOV1
with the Notch signaling pathway. Notch is part of an
evolutionarily conserved pathway that regulates cell differ-
entiation, proliferation and growth [21]. Following ligand
binding, two subsequent proteolytic cleavages by intracel-
lular γ-secretase release the active intracellular domain
of Notch (ICN) from the cell membrane. ICN translocates
to the nucleus and interacts with the CBF-1/RBP-Jκ tran-
scription factor and directs the expression of numerous
downstream target genes, including HES1 and HEY1
[22-25]. In the absence of ICN, CBF-1/RBP-Jκ acts as a
transcriptional repressor by forming a complex that in-
cludes SMRT/NCoR, and HDAC1 [26].
In cancer, Notch signaling, initially shown to be
oncogenic in human T cell acute lymphoblastic leukemia
(T-ALL), and later in other tumors [27-29], was subse-
quently found to function also as a suppressor of tumor
growth, depending on cell lineage or tissue [30-32]. In PC,
several evidences suggest a tumor suppressor role of Notch
signaling [33], including its action in promoting PTEN
activity [34], the downregulation of Notch1 and HEY1
expression in tumors [34,35], the undetectable levels of
Notch1 and ligands in PC cell lines, and the inhibition
of PC cell proliferation by ICN [36]. However, additional
findings, including the elevated levels of Notch ligand
Jagged1 in PC and its association to recurrence, therequirement of Notch2 in the resistance to docetaxel,
and the Notch1 association with aggressive PC, are
suggestive of an oncogenic role [37-39].
In this work, we show that PTOV1 promotes the inva-
sion and anchorage-independent growth of prostate cancer
cells while it acts as a novel repressor of the Notch target
genes HES1 and HEY1. Reciprocally, a constitutively acti-
vated Notch1 receptor decreases anchorage-independent
growth and invasion in vitro. In vivo, PTOV1 antagonizes
Notch function in the Drosophila melanogaster wing, and it
is required for full tumor growth and metastatic potentials
of PC-3 prostate cancer cells in an immunodeficient mouse
model. In prostate tumors, the reciprocal expression pat-
terns observed for PTOV1 and Notch targets support our
in vitro findings.
Results
PTOV1 blunts Notch transcriptional activity
The nuclear localization of PTOV1 was previously associ-
ated with higher proliferative index and tumor grade [6],
suggesting a link between nuclear PTOV1 and cancer pro-
gression in different tumor types, including prostate and
bladder cancers. Others have shown that, in the nucleus,
PTOV1 antagonizes the transcriptional activity of com-
plexes requiring the histone acetyl-transferase CBP [20].
Although CBP was reported to function as a classic
tumor-suppressor gene in the mouse and in prostate
cancer [40-43], other evidences have also suggested a
role in promoting cell proliferation and prostate cancer
progression [44,45]. We thus searched for interactions of
PTOV1 with transcriptional networks known to participate
in the progression of PC and other cancers. Notch is one
such major signaling pathway, regulating the formation of
the normal prostate and involved in PC [36,46,47].
To confirm that prostate cells have active Notch sig-
naling [33], RWPE1 cells, derived from benign prostate
epithelium, and PC-3 prostate cancer cells were treated
with the γ-secretase inhibitor DAPT, known to prevent
Notch processing and transcriptional signaling [48]. This
treatment caused a significant downregulation of the
endogenous Notch target genes HES1 and HEY1, as
determined by real-time RT-PCR (Figure 1A) and a com-
parable decline in the HES1 promoter activity, as deter-
mined by luciferase transactivation assays (Figure 1A). A
similar reduction in HES1-luciferase promoter activity was
observed after the expression of a dominant negative form
of MAML1, a transcriptional co-activator of the Notch
signaling pathway [49]. Similar results were obtained with
LNCaP prostate cancer cells (Additional file 1: Figure S1).
Expression analysis of the four Notch receptors shows that
prostate cell lines have moderate and variable levels of
Notch2, Notch3 and Notch4, while Notch1 is expressed
at lower levels in metastatic cell lines (Additional file 1:
Figure S2). Together, these observations suggest that Notch
Figure 1 Modulation of HES1 and HEY1 expression by Notch signaling and PTOV1 in prostate cell lines. (A) The transcription of HES1 and
HEY1 genes in RWPE1 and PC-3 cells is modulated by the γ-secretase inhibitor DAPT. Cells were treated with DAPT or solvent (CTL) for 4 days and
HES1 or HEY1 transcript levels quantified by real-time RT-PCR. Right: The HES1 promoter is modulated by DAPT and by the negative dominant-MAML1
(dnMAML1). PC-3 cells, transfected with HES-luciferase and TK-Renilla, were either treated with DAPT or co-transfected with ICN and ICN plus dnMAML1
and firefly luciferase activity, normalized to Renilla, determined. (B) Knockdown of PTOV1 in RWPE and PC-3 prostate cells by shRNAs causes the
upregulation of HES1 and HEY1 mRNA. Cells were transduced with shRNA1397 and shRNA1439 lentiviruses and analyzed by real-time RT-PCR.
Values were normalized to RPS14 and for relative values in cells bearing control shRNA.
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and HEY1 genes in these cells. Next, PTOV1 mRNA was
knocked-down in prostate cells by lentiviral transduction
of two distinct short hairpin RNAs (sh1397 and sh1439).
These caused a significant and specific depletion of PTOV1
mRNA and protein levels in RWPE1, in ras-transformed
RWPE2 cells, and in PC-3 cells (Figure 1B and Additional
file 1: Figure S3) accompanied with a significant upregu-
lation of the endogenous HES1 and HEY1 mRNA levels.
Reciprocally, ectopic expression of HA-PTOV1 induced
a significant downregulation of endogenous HES1 and
HEY1 mRNA and protein (Figure 2A) and inhibited the
transactivation of HES1-luciferase by ΔE or ICN, par-
tially and fully activated forms of the Notch1 receptor,
respectively, suggesting that PTOV1 acts as a repressor
downstream of fully processed Notch1 (Figure 2B) in
PC-3, RWPE2 and DU-145 cells. Similar Notch repressor
effects by HA-PTOV1 were observed in HeLa and COS-7
fibroblasts transfected with ΔE or ICN, although not in
HEK293T cells (Additional file 1: Figure S4).PTOV1 interacts with the Notch repressor complex at the
HEY1 and HES1 promoters
We next analyzed whether the repressive function of
PTOV1 on HEY1 and HES1 transcription is associated
with its nuclear localization. We have previously de-
scribed that PTOV1 translocation to the nucleus leads
to increased cell proliferation [4,16]. In the presence of
DAPT, endogenous PTOV1 and also SMRT, a compo-
nent of the Notch repressor complex, showed a mark-
edly increased nuclear localization in PC-3 and LNCaP
cells (Additional file 1: Figure S5), suggesting that under
conditions of inactive Notch nuclear PTOV1 and SMRT
might associate with the Notch repressor complex. As
indicated by pull-down assays using extracts of PC-3
cells transfected with FLAG-SMRT, PTOV1 and SMRT
interacted with each other (Additional file 1: Figure
S5B). Both FLAG-SMRT and endogenous SMRT pro-
teins specifically bound the GST-A and GST-B domains
of PTOV1, with the B domain showing a more efficient
pull-down.
Figure 2 Ectopic overexpression of PTOV1 downregulates endogenous HEY1 and HES1. (A) Cells were transduced with lentivirus for
HA-PTOV1 (black bars) or control lentivirus (white bars) and analyzed for the expression of HES1 and HEY1 by real-time RT-PCR. Inlet: Western
blotting for the detection of ectopic HA-PTOV1 (slower migrating band in transduced cells) and endogenous HES1. (B) The transcriptional repressor
activity of PTOV1 is downstream of Notch receptor processing. PC-3 cells, transfected with the HES-luciferase and TK-Renilla reporter plasmids, were
co-transfected with ΔE (partially processed) or ICN (fully processed) forms of Notch1 without, or with HA-PTOV1, and transactivation of the
HES1-promoter determined by luciferase assays. Statistical significance: * p < 0.05, ** p < 0.005.
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complex was confirmed by co-immunoprecipitation of
PTOV1 and FLAG-RBP-Jκ (a Notch-specific DNA bind-
ing protein), observed only in the presence of DAPT but
not after transfection of constitutively activated Notch
(Figure 3A). To corroborate that PTOV1 interacts with
the Notch-repressor complex at the HEY1 and HES1
promoters, we used chromatin immunoprecipitation
(ChIP). When PC-3 cells were treated with DAPT,
ChIP consistently revealed occupation of these promoters
by endogenous PTOV1 (Figure 3B and Additional file 1:
Figure S6A). RBP-Jκ, but not Notch, was also detected in
these conditions. In contrast, when cells were transfected
with Notch1-ICN, the HEY1 and HES1 promoters were
occupied by ICN and RBP-Jκ, whereas PTOV1 was clearly
absent. ChIP with these proteins yielded no amplifiedbands when using primers for internal HES1 gene se-
quences and irrelevant immunoglobulins did not pull down
DNA associated with these promoters. As an additional
control, the co-repressor NCoR was detected at the HEY1
promoter only in the absence of active Notch (Additional
file 1: Figure S6B).
Next, the association of PTOV1 with additional elements
of the Notch repressor complex was performed by pull-
down experiments. In these experiments, full-length GST-
PTOV1 interacted with RBP-Jκ, HDAC1, HDAC4 and
NCoR (Figure 3C), whereas different components of the
Notch repressor complex showed different binding prefer-
ences for either PTOV1-A domain or B domain, such that
HDAC1 and HDAC4 bound to both PTOV1-A and B
domains, while RBP-Jκ and NCoR showed detectable
binding only to the PTOV1-A domain or the B domain,
Figure 3 (See legend on next page.)
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Figure 3 PTOV1 interacts with RBP-Jκ and the Notch repressor complex at the HEY1 promoter and its repressive function requires
HDACs activity and it is restrained by CBP. (A) PTOV1 interacts with RBP-Jκ. PC-3 cells, transfected with FLAG-RBP-Jκ and HA-PTOV1, were
co-transfected with ICN or treated with DAPT for 4 days. Cell lysates were immunoprecipitated with FLAG antibody or control IgG and blots were
revealed with anti-HA antibody. (B) Endogenous PTOV1 occupies the endogenous HEY1 promoter under conditions of Notch signaling inhibition.
PC-3 cells, transfected with FLAG-RBP-Jκ, were treated with DAPT (left) or co-transfected with ICN (right). Chromatin was immunoprecipitated with
antibodies to PTOV1, FLAG, Notch1, or non-specific IgGs. Associated DNA fragments were analyzed by PCR with primers specific for HEY1 promoter
regions. Primers from intragenic regions of the HES1 gene were used as a specificity control. (C) PTOV1 interacts with the Notch repressor complex.
FLAG-HDAC1, FLAG-HDAC4, FLAG-NCoR and FLAG-RBP-Jκ were separately transfected into PC-3 cells and tested for interaction with GST-PTOV1
(left panel) or GST-A domain, GST-B domain (right panel) or control GST beads. Bound proteins were analyzed by Western blotting with anti-FLAG. (D)
PTOV1 repressor activity requires HDACs activity. Cells, transfected with HES1-luciferase, Renilla and the plasmids indicated, were treated with the HDAC
inhibitor trichostatin A (TSA) for 48 h. Lysates were used in transactivation assays for firefly luciferase activity (E) Overexpression of the CBP
acetyl-transferase, but not p300, overcomes the repressor activity of PTOV1 on the HES1 promoter. Cells, transfected with p300 or CBP plus
the indicated plasmids, were used in HES1-driven luciferase transactivation assays. (F) PTOV1 interacts with CBP but not with p300. Lysates
from cells transfected with FLAG -PTOV1 and HA-CBP (top), or HA-p300 (bottom), were immunoprecipitated with antibody to HA, or control
IgG, and analyzed by Western blotting.
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that, under conditions of inactive Notch, the nuclear
localization of endogenous PTOV1 is increased and is
associated with several components of the Notch repres-
sor complex at the HEY1 and HES1 promoters. Activated
Notch, on the other hand, provokes the dismissal of
PTOV1 from these promoters.
PTOV1 repressor activity requires active histone deacetylases
The repressive function of PTOV1 might be linked to
the concurrent recruitment to these promoters of co-
repressors, such as histone deacetylases (HDACs). To
determine this, we treated PC-3 cells with trichostatin A
(TSA), an inhibitor of HDACs [50] that relieves repression
at Notch responsive promoters [51]. TSA significantly
decreased the repression exerted by HA-PTOV1 on
the HES1 promoter, indicating that the PTOV1 repressive
function requires active HDACs (Figure 3D). Conversely,
transfection of the acetyl transferase CBP, but not p300,
enhanced the transactivation of HES1-luciferase promoted
by Notch1 and completely abolished the repressive ac-
tivity of PTOV1 (Figure 3E). Consistently, PTOV1 co-
immunoprecipitated with CBP (Figure 3F) [20], but not
with p300. Thus, the repressive action of PTOV1 on the
HES1 promoter requires active HDACs, it is enhanced
by p300 and is overcome by the expression of CBP.
PTOV1 Suppresses notch function in drosophila
melanogaster
To further corroborate the observed functional interactions
between PTOV1 and the Notch pathway, we tested the
effects of the expression of human PTOV1 on Notch
mutant-dependent Drosophila wing patterns. The Notch
mutant phenotype was first described in flies, where
dosing of Notch produces specific patterns throughout
Drosophila development [21,52,53]. We generated trans-
genic flies containing the full-length human PTOV1
cDNA tagged with HA (hPTOV1) under the control of
the Upstream Activating Sequence (UAS) promoter todirect the expression of hPTOV1 using the Gal4/UAS
system [54]. The expression of hPTOV1 was analyzed
using the engrailed-Gal4UAS-GFP line that directs the
expression of GFP and hPTOV1 only in the posterior part
of the third instar larval wing imaginal discs (Figure 4A).
To study the effect of hPTOV1 on patterns associated
with loss-of-function of Notch, we used the N55e11 allele, a
Notch null mutant that promotes notched wings [53].
When UAS-HA-hPTOV1 was expressed in these heterozy-
gous flies using the nubbin-Gal4 line that drives expres-
sion in the central part of the wing disc during larval
development, we observed a significant increase in the
number of notches per wing (Figure 4B). The Notch gain-
of-function phenotype (NAx-M1 allele) results in failure to
complete development of the most distal part of vein L5
and in a significant increase of wing size, when cultured at
25°C [53]. Expression of hPTOV1 in the NAx-M1 back-
ground restored the L5 vein and the wing size to wild-type
patterns, indicating suppression by hPTOV1 of the effects
promoted by constitutively active Notch (Figure 4C-D).
These results support the conclusion that PTOV1 acts as a
negative regulator of the Notch pathway.
PTOV1 is pro-oncogenic in prostate cancer cells
The expression of HA-PTOV1 in PC-3 cells significantly
increased invasion compared to control cells and, recipro-
cally, cells expressing shPTOV1 showed that this protein
is required for optimal cell invasion (Figure 5A). Import-
antly, the gain in invasiveness prompted by overexpression
of PTOV1 was abrogated by the concomitant expression
of ICN or ΔE. Similarly, knockdown of PTOV1 caused a
significant reduction in the ability of PC-3 cells to from
spheroids, while expression of HA-PTOV1 stimulated
spheroid formation (Figure 5B). On the other hand,
constitutive expression of a full-length form of Notch1
in PC-3 cells, that express low endogenous levels of this
gene (Additional file 1: Figure S2), caused a significant re-
duction in their capacity to form spheroids (Figure 5C).
These results suggest that PTOV1 promotes, and Notch
Figure 4 PTOV1 antagonizes Notch activity in the Drosophila wing. (A) Expression of hPTOV1 in engrailed-Gal4UAS-GFP; UAS-HA-hPTOV1 wing
imaginal discs. To confirm the activity of the transgene, the ectopic expression of hPTOV1 from the UAS-HA-hPTOV1 was examined. The engrailed-Gal4
line, which drives UAS-transgene expression only in the posterior compartment of the wing disc, allows to compare the levels of expression in anterior
versus posterior compartments in the same tissue (imaginal disc). The expression of the transgene was observed by (1) co-activation of a UAS-GFP, (2)
immuno detection of HA and (3) antibodies to PTOV1. Absence of staining in the anterior (left) half of the disc contrasts with positive staining in the
posterior (right) half, demonstrating the ectopic expression of PTOV1 driven by engrailed-Gal4. (B) Overxpression of hPTOV1 exacerbates the effects of
loss-of-function (LOF) of Notch. Notch LOF allele N55e11 causes a notch at the wing edge (arrowhead, left and middle panels) that is exacerbated by
expression of hPTOV1 (arrowheads, right panel). (C) Expression of hPTOV1 suppresses the effects of Notch gain-of-function (GOF). The GOF Notch allele
NAx-M1 causes defects in the L5 vein (arrowhead, left and middle panels), suppressed by expression of hPTOV1 (arrowhead, right panel). A wild type (wt)
wing is shown as control. (D) Histogram showing the quantification of the wing areas for each genotype (n > 30) (*** p < 0.0005).
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with PC progression. The contrasting activities of PTOV1
and HES1 and HEY1 were also tested in HaCaT trans-
formed skin keratinocytes, a cellular model in which
Notch has known tumor suppressor functions [31,55]. Inthese cells, HA-PTOV1 significantly repressed HES1 and
HEY1 expression and promoted cell proliferation and
spheroid formation (Additional file 1: Figure S7). Recip-
rocally, knockdown of PTOV1 in HaCaT cells significantly
increased the expression of these genes and decreased
Figure 5 HA-PTOV1 overexpression promotes invasion and
anchorage-independent growth of PC-3 cells in contrast to the
effects of exogenous Notch1 expression. (A) PTOV1 induces
in vitro cell invasion, in contrast to the inhibition caused by Notch1.
PC-3 cells were transiently transfected with 5 μg of the indicated
plasmids and/or 5μg of DNA carrier (CTL) and treated with DAPT or
solvent for three days before trypsinization and plating on
Matrigel-coated Transwell wells. After 24 h, invading cells were
stained with Hoechst and scored. Short hairpin sh1397 was used
to knockdown PTOV1 expression. Assays were performed in
triplicate in at least two independent experiments. (B) PTOV1
promotes anchorage-independent growth of PC-3 cells. Cells stably
knocked down for PTOV1 grew significantly fewer spheroids than
control cells. In contrast, cells stably expressing HA-PTOV1 formed
significantly more spheroids than cells transduced with control
lentivirus. (C) Notch1 overexpression significantly decreases
anchorage-independent growth of PC-3 cells. Independent clones
c4 and c15, with stable expression of Notch1 as shown by Western
blotting, formed significantly fewer spheroids than control cells
transfected with control pcDNA3 vector. S2 and S3 indicate partial
and active forms of Notch1 receptor. * p < 0.05, ** p < 0.005,
*** p < 0.0005.
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high levels of PTOV1 suppress Notch signaling and in-
duce oncogenic properties in different cellular contexts.
PTOV1 is required for tumorigenesis and metastasis of
PC-3 prostate cancer cells
We next tested whether PTOV1 is required for the
tumorigenic and metastatic properties of PC-3 cells. Cells
knocked down for PTOV1 grew significantly smaller (p =
0.0095) subcutaneous tumors in SCID-beige mice com-
pared to control cells transduced with a non-targeting
shRNA (Figure 6A). Immunohistochemical analysis of
tumors derived from shPTOV1 cells showed strongly
increased levels of HES1 and HEY1 proteins as compared
to control cells (Figure 6B), consistent with a negative
regulation of their expression by PTOV1. In addition, dis-
tant metastases of PTOV1 knockdown cells were detected
with a significant delay (p = 0.001) as compared to control
cells. These results provide evidence that PTOV1 is re-
quired for the expression of full tumorigenic and meta-
static potentials of PC-3 cells in vivo.
Reciprocal expression patterns of PTOV1 and HEY1 in
prostate cancer
To know the relative contributions of PTOV1 and Notch
signaling to malignancy in PC, we analyzed the expression
of PTOV1, HEY1 and HES1 in 45 prostate adenocarcin-
omas and control associated benign peripheral zone (BPZ)
by real-time RT-PCR. As expected [1,4], PTOV1 expres-
sion was significantly higher in cancer with respect to BPZ
(Figure 7A). In contrast, the expression levels of HEY1
were significantly lower in tumors compared to adjacent
BPZ, such that a significant inverse correlation was estab-
lished between the expression levels of HEY1 and PTOV1
Figure 6 (See legend on next page.)
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Figure 6 Knockdown of PTOV1 in prostate cancer cells inhibits tumor growth and metastasis of PC-3 cells in immunodeficient mice.
(A) PTOV1 is required for optimal tumor formation of PC-3 cells in vivo. PC-3 cells with integrated luciferase gene (3 x106), knocked down for
PTOV1 (n = 5) by sh1397 or control lentivirus (n = 5), were implanted subcutaneously into the right flank of SCID-beige male mice and monitored
by in vivo bio-luminescent imaging. Mean values + SEM are displayed. Statistically significant differences in the growth of knockdown vs. control
cells were observed. ** p = 0.001. (B) Immunohistochemistry of explanted tumors. A strongly decreased expression of PTOV1 is detected in tumors
formed by shPTOV1 cells vs shControl derived tumors. In contrast, tumors derived from shPTOV1 cells express high levels of HES1 and HEY1
proteins compared to shControl and grew metasases at significantly later times (p = 0.001) as compared to control cells.
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second Notch transcriptional target, HES1, were not
significantly altered in tumors compared to BPZ.
Tumor tissues were analyzed at single-cell level by immu-
nohistochemistry for the expression of PTOV1, HEY1 and
HES1 proteins on serial sections from 20 primary tumors
(n = 10 with Gleason < 7 and n = 10 with Gleason > 7) and
16 lymph node metastases. Epithelial cells from BPZ
showed undetectable or faint staining for PTOV1, while a
gradual increase in staining intensity was observed from
HGPIN lesions to adenocarcinoma lesions, which gener-
ally showed a strong staining (Figure 7B-C). In metastases,
the staining for PTOV1 was also significantly stronger
than in BPZ. In contrast, the expression of HEY1 followed
a pattern almost reciprocal to that of PTOV1 and it was
significantly stronger in epithelial cells in BPZ and pre-
malignant HGPIN compared to cancer and metastasis
(Figure 7B-C), confirming the results at the mRNA level.
HES1 expression did not show notable differences in
intensity between BPZ and tumor areas, although cancer-
ous cells showed a prevalent cytoplasmic localization
(Figure 7C). Nevertheless, HES1 expression significantly
decreased in metastases (Figure 7B-C), confirming a re-
ciprocal expression pattern between PTOV1 and HES1
in metastatic lesions.
The above results bear not only on any putative roles
of PTOV1 in the regulation of HES1 and HEY1 and in
prostate cancer progression, but also on the controversial
role of Notch in PC [33-39]. Although the results of im-
munohistochemical analysis show mere correlations be-
tween high PTOV1 and low HES1 and HEY1 levels, when
taken in the context of the Notch repressor function for
PTOV1 described above in cellular models, they are con-
sistent with the notion that high levels of PTOV1 repress
the transcriptional activity of Notch in metastatic prostate
cancer.
Discussion
A role for PTOV1 in tumor progression was suggested by
previous findings showing its overexpression in PC and
other neoplasms in association with increased prolifera-
tion rates and higher histological grade [1-6]. Here, we
provide evidences suggesting that the pro-oncogenic func-
tion of PTOV1 is associated with a downregulation of the
Notch target genes HEY1 and HES1. The functional linkthat we have found between (i) the inhibition of Notch
phenotypes in the Drosophila wing, (ii) the upregulation
of endogenous HES1 and HEY1 in cells knockdown for
PTOV1 and, reciprocally, their inhibition caused by ec-
topic expression of PTOV1 in PC cells and HaCaT ker-
atinocytes, where Notch acts as tumor suppressor [55],
and (iii) the occupancy by PTOV1 of the HES1 and
HEY1 promoters in cells with inactive Notch receptor,
provide strong evidences in support of the participation of
PTOV1 in the regulation of Notch signaling.
PTOV1 shares similarities with SMRT, a known Notch
co-repressor, in the repressive activity on HEY1 and HES1
promoters, the requirement for HDACs and the coun-
teracting effects of histone acetyl transferases [56,57].
However, while SMRT is excluded from the nucleus by
MEKK-1/MEK-1 or IKKα signaling [56,58], PTOV1 trans-
locates to the nucleus upon stimulation with growth fac-
tors [4,16], and while SMRT is expressed at similar levels
in BPZ and PC [59], PTOV1 is overexpressed in PC. We
propose that while SMRT is generally required for the
repression of Notch transcriptional activity and other
signaling pathways, PTOV1 might be a facultative tran-
scriptional co-repressor with a more restricted scope.
Indeed, in response to certain mitogenic signals, PTOV1
translocates to the nucleus, where it could facilitate the
transcription of genes necessary for proliferation [4,16],
and invasion (Figure 5A, 5C) while simultaneously repres-
sing Notch targets HEY1 and HES1 genes, as shown in the
current study. Reciprocally, Notch activation excludes
PTOV1 from these promoters, thus permitting the en-
gagement of Notch-dependent programs while pre-
venting the activation of genes that regulate general
proliferation and invasion (Figure 5A, 5C). The function
of PTOV1 as a Notch co-repressor could also differ from
that of SKIP [60], since we show here that PTOV1 interacts
with the Notch repressor complex, but not with Notch1.
Similarly, SHARP, another Notch co-repressor, also in-
teracts with the same inhibitors as PTOV1 [51,61,62],
but shows different expression patterns in human tu-
mors [6,61].
The Notch pathway is regulated by positive and nega-
tive signals [21]. Although we have shown that PTOV1
can repress the Notch-dependent expression of HEY1
and HES1 in the several cell lines tested, these genes are
under the regulation of additional pathways in different
Figure 7 PTOV1 displays expression patterns reciprocal to those of HEY1 and HES1 in benign prostate, primary prostate carcinoma
and metastasis. (A) PTOV1 transcripts levels increases from normal prostate to primary prostate cancer samples, while HEY1 expression declines
from normal to neoplastic tissues. mRNA from 43 prostate adenocarcinomas (PCa) and their corresponding benign epithelial glands from the
peripheral zone (BPZ) were analyzed by real-time PCR using specific primers and probes for HES1, HEY1 or PTOV1. Values represent mean + SEM of
mRNA expression relative to RPS14 control. PTOV1 levels are significantly increased in PCa compared to BPZ. HEY1 levels in BPZ are significantly
decreased in PCa. A significant inverse correlation between the expression levels of HEY1 and PTOV1 is evidenced (Pearson coefficient = 0.87). (B)
The expression levels of PTOV1, as determined by immunohistochemistry, increases along with metastatic progression of PCa, while expression
levels of HEY1 and HES1 declines with progression. Protein expression levels were assigned semiquantitative values by the Hscore method in
benign epithelium (BPZ), pre-malignant HGPIN lesions, PCa, and 16 lymph node metastasis (Met). (C) Representative images from immunohistochemical
staining of serial sections from PCa and metastasis (Met) with specific antibodies to HEY1, HES1 or PTOV1. Slides were counterstained with hematoxylin.
PTOV1 staining is low or undetectable in BPZ, and strong expression is observed in PCa and Met. HES1 and HEY1 show strong staining in benign epithelial
glands in BPZ and HGPINs. A significantly decreased staining intensity is observed for HEY1 in cancerous areas of PCa and metastasis, relative to BPZ.
Staining intensity for HES1 is comparable between epithelial glands of BPZ, HGPIN and cancerous areas of PCa, but the intensity is significantly weaker
in metastases (Met). Bars indicate average Hscore values.* p < 0.05, ** p < 0.005,*** p < 0.0005.
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http://www.molecular-cancer.com/content/13/1/74cell types or tissues, as suggested by the observation that
HES1 expression in Notch1 knockout and in CBF-1/
RBP-Jκ knockout mutants is not downregulated [63,64].
Thus, although HES1 is a bona fide Notch/ RBP-Jκ tar-
get, it is also regulated by different signaling cascades in
tissues [65] and in fibroblasts [66,67].
The evidence presented here suggests that the recruit-
ment of the histone acetyl transferase CBP to the HES1
promoter overcomes the repressive action of PTOV1 on
HES1 transcription. In contrast, p300, another major
histone acetyl transferase, appears to enhance the tran-
scriptional repression of HES1 by PTOV1. This suggests
that these two histone acetyl transferases determine op-
posing transcriptional states of the HES1 promoter, with
CBP favoring a state of active transcription and p300 a
state of transcriptional repression. Recent findings indicate
that CBP has a stronger trans-activating function than
p300 on genes whose products are negative transcription
regulators, such as HES1 [68]. This is consistent with our
observations that PTOV1 and p300 cooperate to repress
HES1 transcription, while CBP relieves this repression.
Of interest, p300 has been described as a positive inducer
of prostate cancer progression, while CBP has been de-
scribed as a tumor suppressor in the prostate [42,44,69,70].
Together with our observations that PTOV1 expression
correlates positively, and HES1 expression negatively, with
prostate cancer progression, these evidences may suggest
that both PTOV1 and p300, which antagonize Notch target
transactivation, function as positive inducers of prostate
cancer progression, whereas the Notch signaling and the
HES1 activator CBP function as suppressors of prostate
cancer establishment and/or progression.
Our evidences also suggest that the function of PTOV1
as a repressor of Notch signaling may have significant
consequences for PC progression. Knockdown of PTOV1
in PC-3 cells led to a strong upregulation of HES1 and
HEY1 both in vitro and in cells implanted in SCID-beige
mice, accompanied with a significant delay in tumor
growth and metastatic spread. These pro-oncogenic func-
tions of PTOV1 were also observed in HaCaT keratino-
cytes, in which Notch behaves as a tumor suppressor [31].
In addition, our evidences suggest that high levels of
PTOV1 downregulate HES1 and HEY1 in PC cells by
promoting the recruitment of a transcription repressive
complex to their promoters. This PTOV1-mediated re-
pression requires active HDACs and is counteracted by
the histone acetyl transferase CBP but not p300, suggest-
ing that PTOV1 and Notch activities might be modulated
by differential expression of these two enzymes.
In human tissues, we have found evidence of active
Notch signaling in the normal prostate epithelium, as
attested by the relatively high levels of expression of HES1
and HEY1, as expected [36,46], while PC metastatic sam-
ples expressed significantly lower levels of these proteins,suggestive of a Notch repressed state. PTOV1, on the
other hand, showed expression patterns almost reciprocal
of those for HEY1 or HES1: low levels or absent in normal
epithelium and high levels in metastases. Our observa-
tions lend support to a tumor suppressor function of
Notch signaling in PC, similarly to its previously dem-
onstrated role in skin, myeloid leukemia and cervical
carcinoma cells [30,55,71,72]. Additional evidences are
also suggestive of a tumor suppressor function of Notch
in PC, including the observations of downregulation of
HEY1 and of activated Notch1 [34,35], and prevention
of luminal cell differentiation and induction of prolifera-
tion in Notch1 knock-out models [35,39]. On the other
hand, the activation of Notch2 detected in rare metastatic
cells [38], and the overexpression of the Notch ligand
Jagged-1 found in metastasis, suggest an oncogenic role
for Notch in PC, although no assessment on Notch signal-
ing was done in the same tumors [37].
Conclusions
Taken together, our observations are compatible with a
model whereby PTOV1 contributes to the initiation and
progression of PC in part by counteracting the expression
of HEY1 and HES1 genes, thus decreasing Notch signaling.
These findings are also supportive of a tumor suppressor
role of Notch in prostate cancer progression [33-36].
Methods
Cell culture, transfection and antibodies
Cell lines were obtained from the American Type Culture
collection (Rockville, MD). PC-3, DU-145 and LNCaP
prostate cancer cells were maintained in RPMI medium
supplemented with 10% heat-inactivated FBS, 2 mM L-
glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin,
and 0.1 mM non-essential amino acids (Life Technologies,
Grand Island, NY) at 37 ºC in an atmosphere of 5% CO2.
COS-7 fibroblasts and HaCaT keratinocytes were main-
tained in Dulbecco’s modified Eagle’s medium supple-
mented as above. Human benign prostate-derived epithelial
cells RWPE1 and RWPE2 [73] were maintained in
Keratinocyte-Serum-Free Medium (Invitrogen, Carlsbad,
CA) supplemented with 1 μg/mL human recombinant
epidermal growth factor and 10 μg/mL bovine pituitary
extract. COS-7 and HeLa cells were transiently transfected
for 48 h using Lipofectamine Plus reagents (Invitrogen).
Prostate-derived cells were transiently transfected using
the TransIT®-Prostate Transfection Kit (Mirus Bio, Madison,
WI). Cells stably transduced by HA-PTOV1 lentivirus or
control were selected by flow citometry for GFP-positive
cells. PC-3 cell clones c4 and c15, stably expressing
Notch1, were obtained by transfection of pcDNA3-
Notch1 and selection for two weeks in media containing
G418. Control clones, transfected with empty vector, were
also selected. DAPT (Sigma-Aldrich, St Louis, MO) was
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bodies to SMRT, HES1 and HEY1 were from Millipore.
Antibodies to Notch1 (C-20), GST (1E5) and actin (I19)
were from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibody to γ − secretase-processed Notch1 recognizing
Val 1744 was from Cell Signaling. Anti-Flag (M2), Anti-HA
and anti β-tubulin were from Sigma-Aldrich.
Plasmids
Full-length human PTOV1 cDNA was obtained from the I.
M.A.G.E. Clone Consortium. Constructs harboring the
PTOV1 gene were described previously [4,16]. pIRE-LTXT
vector was a generous gift of Dr. Luis Álvarez-Vallina.
Partially activated Notch1 ΔE and fully activated intra-
cellular Notch1 (ICN) constructs were kindly provided
by Raphael Kopan. Full-length Notch1 in pcDNA3 (FlN1)
was a kind gift of Jon Aster.
RNA interference and lentivirus production
Short-hairpin shRNA sequences 1397 and 1439 (Sigma-
Aldrich), targeting the human PTOV1 mRNA are shown
in Additional file 1: Table S1. Cells transduced with len-
tiviral particles, were selected with 1 μg/mL puromycin
(Sigma-Aldrich) for seven days.
Transactivation assays
Cells, seeded in 12 well plates, were transfected with test
plasmids plus HES1-Luc, or HEY-Luc (0.4 μg), as reporter
plasmids and TK-Renilla (0.2 μg) as an internal control
for transfection efficiency. The total amount of DNA was
kept constant in each experiment by including control
pCMV-HA vector. Luciferase assays were performed 48 h
after transfection, following the manufacturer’s instruc-
tions (Dual Luciferase Reporter Assay Systems, Promega,
Madison, WI). Firefly luciferase values were normalized to
Renilla values. Each condition was tested in three inde-
pendent experiments performed in triplicate.
Real-time RT-PCR
A total of 43 prostate adenocarcinomas from radical
prostatectomies performed for T2 to T3 stage tumors
were obtained from the archives of the Department of
Pathology, Clinic Hospital of Barcelona. The Gleason
sum score ranged from 4 to 9 and were stratified as
grade < 7 (7 patients) versus > 7 (26 patients). Prostatic
tissue from the benign peripheral zone (BPZ) could be
evaluated in 10 specimens. Total RNA was prepared
from cells or tissues with RNeasy kits (Qiagen, Valencia,
CA) and cDNA synthesis was performed with the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). Real-time RT-PCR was per-
formed with the Universal Probe Library system (Roche,
Mannheim, Germany) on a LightCycler 480 RealTime
PCR instrument (Roche). Specific primers used are shownin Supplementary Information Additional file 1: Table S2.
Since the relative amplification efficiencies of target and
reference samples were found to be approximately equal,
the ΔΔCt method was applied to estimate relative tran-
script levels. RPS14 amplification levels were used as
internal references. Data in triplicates were calculated
and presented as mean + SEM.
Immunofluorescence
Immunofluorescence assays of cultured cells were per-
formed as described [16]. DNA was stained with Hoechst
33258. Fluorescent images were captured by confocal mi-
croscopy (FV1000, Olympus, Tokyo, Japan) and quantified
with Olympus Fluorview software.
Chromatin immunoprecipitation (ChIP)
Chromatin was immunoprecipitated using EZ-chip Chro-
matin Immuno Precipitation kit (Millipore, Billerica, MA).
Briefly, after a mild formaldehyde crosslinking step, cells
were sonicated, lysates incubated with primary antibodies
and precipitated with protein A/G-Sepharose. Crosslinking
of DNA-protein complexes was reversed, DNA purified
and used as a template for PCR reactions. Primers used for
PCR in ChIP experiments are described in Additional file 1:
Table S3.
Pull-down assays
GST-fusion proteins expressed in Escherichia coli BL-21
strain were purified and stored at -80°C. Pull down assays
were performed as described [16]. Protein complexes were
analyzed by SDS-PAGE and Western blotting.
Western blotting
Western blotting was performed as described previously
[16]. Reactivity was detected with a chemiluminescent
substrate (ECL, Amersham Biosciences).
In vitro invasion assays
Assays were performed using growth factor-reduced
Matrigel-coated 8-μm pore size Transwell chambers (BD
Bioscience, Franklin Lakes, NJ). Invasive cells at the
bottom chamber were stained with Hoechst 33258 and
scored. Each condition was tested in triplicate.
Spheroid formation assays
Cells (103 cells/well) were plated in triplicate samples in
24-well Ultra Low Attachment plates (Corning) in 1 mL
of complete medium containing 0.75% methylcellulose
(Sigma-Aldrich) and grown for 14 days before counting.
In vivo tumorigenic assays
The firefly luciferase gene was integrated into the gen-
ome of PC-3 cells by lentiviral transduction of a pIRE-
LTXT-based construct. shControl and PC-3 shPTOV1
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cutaneously implanted in the rear right flank of 6 week-
old male SCID-Beige mice (n = 5 for each cell line) (Charles
River Laboratories, Barcelona, Spain). All animal experi-
mental procedures were approved by the Vall d’Hebron
Hospital Animal Experimentation Ethic Committee. Tumor
growth was monitored twice a week by caliper measure-
ments (D × d2/2, where D is the major diameter and d the
minor diameter) and in vivo bioluminescence imaging
(BLI). BLI intensity was quantified in photons per second
(ph/s) using the IVIS Spectrum Imaging System equipped
with the Living Image 4.0 software (Caliper Life Sciences).
After reaching 1.5 cm in diameter, mice were anesthetized
and primary tumors excised, weighted and imaged by
ex vivo BLI. Tumor/control (T/C) weight ratio was calcu-
lated by dividing the median value of the tumor weight of
the test tumors by the median value of the control group.
Mice were monitored for metastatic growth after tumor
excision to detect secondary metastases by in vivo bio-
luminescent imaging using the IVIS Spectrum. Experi-
mental end-point was metastasis detection, after which
mice were euthanized and selected tissues analyzed by
ex vivo BLI and then processed for histopathology.
Immunohistochemistry
Samples from 20 prostate adenocarcinomas, 10 with
Gleason < 7 and 10 with Gleason > 7, plus 16 metastases
to regional lymph nodes were obtained from the archives
of the Department of Pathology, Hospital Vall d’Hebron
and the Clinic Hospital of Barcelona. The study was
approved by the Institutional Ethical Boards at the Vall
d´Hebron Research Institute and the Clinic Hospital.
Four μm consecutive or nearly consecutive sections were
analyzed by immunohistochemistry with the avidin-biotin
peroxidase method. As a negative control, non-specific
rabbit antibody was used and gave clean negative results
in all cases tested. Positivity was considered when > 10% of
the cells showed unequivocal staining. PTOV1, HEY1 and
HES1 expression were evaluated in a semiquantitative man-
ner [6,8], whereby the levels of expression are represented
as the percentage of positive cells and the intensity of
staining [Hscore = 1 × (% weak) + 2 × (% moderate) + 3 ×
(% intense) in a range between 0 and 300] [6,8],
Fly strains and experiments
The Notch alleles N 55e11 and N Ax-M1 and nubbin-Gal4
and engrailed-Gal4UAS-GFP lines were obtained from
the Bloomington Stock Center (Indiana University,
Bloomington, IN). The generation of the transgenic lines
is described in the Supporting Information. For immuno-
histochemistry, third instar larval discs were dissected,
fixed and processed for staining with specific antibodies.
Quantification of wing areas was performed using the NIH
ImageJ software.Statistics
Results are expressed as means + standard errors of the
means. The 2-tailed Student’s t test was used for statistical
analysis. A p value < 0.05 was taken as the level of signifi-
cance. To analyze distributions of qualitative variables,
the Pearson coefficient was used. These analyses were
performed using the Excel package.Additional file
Additional file 1: Table S1. shRNA sequences used for PTOV1
knockdown. Table 2SA. Primers used for real-time RT-PCR using Universal
Probe Library (Roche). SB. Primers used for real-time RT-PCR using SYBR Green
(Life Technology). Table S3. Primers used for Chromatin inmunoprecipitation
(ChIP). Figure S1. The levels of transcription of the Notch target genes HES1
and HEY1 in LNCaP prostate cancer cells are modulated by the γ-secretase
inhibitor DAPT. Figure S2. The four different Notch receptors are expressed
at variable levels in human prostate cell lines. Figure S3. Western blots
illustrating the degree of PTOV1 knockdown in RWPE1, RWPE2 and PC-3
cells by shRNA1397 and shRNA1439. Figure S4. PTOV1 represses Notch
dependent HES1 expression in HeLa and COS-7 cells. Figure S5. PTOV1
interacts with the Notch co-repressor SMRT. Figure S6(A) Occupancy by
PTOV1 of the endogenous HES1 promoter under inhibition of Notch
signaling. S6(B) Occupancy by the co-repressor NCoR of the endogenous
HEY1 promoter under inhibition of Notch signaling. Figure S7. PTOV1
promotes proliferation, anchorage-independent growth and repression of
Notch targets genes HES1 and HEY1 in HaCaT transformed keratinocytes.Abbreviations
PC: Prostate cancer; DAPT: N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
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